Calcipotriene/betamethasone dipropionate foam:
primary evidence supporting its use in patients
with psoriasis vulgaris. A narrative review

Joanna Narbutt; Rafał Czajkowski; Aleksandra Lesiak; Witold Owczarek; Adam Reich; Jacek Szepietowski

doi:10.5114/ada.2021.110062

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2021
vol. 38

Send email

Copy url:

abstract:

Review paper

Calcipotriene/betamethasone dipropionate foam: primary evidence supporting its use in patients with psoriasis vulgaris. A narrative review

Joanna Narbutt

¹

,

Rafał Czajkowski

²

,

Aleksandra Lesiak

¹

,

Witold Owczarek

³

,

Adam Reich

⁴

,

Jacek C. Szepietowski

⁵

Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland
Clinic of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Faculty of Medicine in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
Department of Dermatology, Military Institute of Medicine, Warsaw, Poland
Department of Dermatology, University of Rzeszow, Rzeszow, Poland
Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland

Adv Dermatol Allergol 2021; XXXVIII (5): 727-733

DOI: https://doi.org/10.5114/ada.2021.110062

Online publish date: 2021/11/05

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Narbutt J, Czajkowski R, Lesiak A, Owczarek W, Reich A, Szepietowski JC. Calcipotriene/betamethasone dipropionate foam:
primary evidence supporting its use in patients
with psoriasis vulgaris. A narrative review. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2021;38(5):727-733. doi:10.5114/ada.2021.110062.

APA

Narbutt, J., Czajkowski, R., Lesiak, A., Owczarek, W., Reich, A.,  & Szepietowski, J. C. (2021). Calcipotriene/betamethasone dipropionate foam:
primary evidence supporting its use in patients
with psoriasis vulgaris. A narrative review. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 38(5), 727-733. https://doi.org/10.5114/ada.2021.110062

Chicago

Narbutt, Joanna, Rafał Czajkowski, Aleksandra Lesiak, Witold Owczarek, Adam Reich,  and Jacek C Szepietowski. 2021. "Calcipotriene/betamethasone dipropionate foam:
primary evidence supporting its use in patients
with psoriasis vulgaris. A narrative review". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 38 (5): 727-733. doi:10.5114/ada.2021.110062.

Harvard

Narbutt, J., Czajkowski, R., Lesiak, A., Owczarek, W., Reich, A.,  and Szepietowski, J. (2021). Calcipotriene/betamethasone dipropionate foam:
primary evidence supporting its use in patients
with psoriasis vulgaris. A narrative review. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 38(5), pp.727-733. https://doi.org/10.5114/ada.2021.110062

MLA

Narbutt, Joanna et al. "Calcipotriene/betamethasone dipropionate foam:
primary evidence supporting its use in patients
with psoriasis vulgaris. A narrative review." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 38, no. 5, 2021, pp. 727-733. doi:10.5114/ada.2021.110062.

Vancouver

Narbutt J, Czajkowski R, Lesiak A, Owczarek W, Reich A, Szepietowski J. Calcipotriene/betamethasone dipropionate foam:
primary evidence supporting its use in patients
with psoriasis vulgaris. A narrative review. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2021;38(5):727-733. doi:10.5114/ada.2021.110062.

Psoriasis vulgaris is a chronic, immune-mediated disorder, which has a substantial impact on all aspects of patients’ quality of life. In most patients, the disease is mild to moderate and is successfully treated with topical agents. The most common therapy involves a vitamin D3 analogue (calcipotriene) in combination with a synthetic corticosteroid (betamethasone dipropionate). The aerosol vehicle (foam) with softening properties is another formulation of this combination drug, apart from ointment and gel, expanding the therapeutic options available to patients with psoriasis. The article describes the pharmacokinetic and pharmacodynamic properties of calcipotriene/betamethasone dipropionate foam. The results of the key randomised clinical studies investigating the efficacy, including patients’ quality of life and safety of the foam versus ointment, gel and either active ingredient in foam vehicle are presented. In addition, the results of a study on maintenance treatment with calcipotriene/betamethasone dipropionate foam as well as reports on real-world use of this medicine in patients with psoriasis, are discussed.

keywords:

Calcipotriene/betamethasone dipropionate foam: primary evidence supporting its use in patients with psoriasis vulgaris. A narrative review

Joanna Narbutt 1 , Rafał Czajkowski 2 , Aleksandra Lesiak 1 , Witold Owczarek 3 , Adam Reich 4 , Jacek C. Szepietowski 5

psoriasis vulgaris, calcipotriene, betamethasone dipropionate, foam, topical administration

Joanna Narbutt

¹

,

Rafał Czajkowski

²

,

Aleksandra Lesiak

¹

,

Witold Owczarek

³

,

Adam Reich

⁴

,

Jacek C. Szepietowski

⁵